News Releases

Date	Title	View
September 3, 2024	Alumis to Participate in Upcoming September Investor Conferences	PDF Version
August 13, 2024	Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements	PDF Version
July 29, 2024	Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis	PDF Version
June 27, 2024	Alumis Announces Pricing of Initial Public Offering	PDF Version
April 30, 2024	Alumis Announces First Participant Dosed in Phase 1 Clinical Trial of CNS Penetrant Allosteric TYK2 Inhibitor A-005	PDF Version
March 11, 2024	Alumis to Participate in the 2024 Leerink Partners Global Biopharma Conference	PDF Version
March 9, 2024	Alumis Presents Positive Data from Phase 2 Clinical Trial of ESK-001, an Oral Allosteric TYK2 Inhibitor for the Treatment of Plaque Psoriasis, at AAD Annual Meeting	PDF Version
March 6, 2024	Alumis Announces Upsized $259M Series C Financing to Advance Clinical-stage Pipeline of Oral Therapies Designed to Address Immune Dysfunction	PDF Version
March 4, 2024	Alumis Announces Late-Breaker Psoriasis Phase 2 Data Presentation for Allosteric TYK2 Inhibitor ESK-001 at the American Academy of Dermatology 2024 Annual Meeting	PDF Version
March 1, 2024	Alumis Presents Preclinical Data for Allosteric TYK2 Inhibitor A-005 at ACTRIMS	PDF Version